Treatment
DTG/3TC clinical trials
We’re tracking 6 recruiting studies that include DTG/3TC, each written for real people, not researchers, below.
Recruiting studies
- NCT07031063RecruitingPhase 4
HIV treatment study for people starting therapy
This study compares two HIV medications (DTG/3TC and BIC/TAF/FTC) to see which works better and is safer for people who have never taken HIV treatment before. It may help you find a once-daily pill that controls the virus and has fewer side effects.
Mexico City, AzcapotzalcoAges 18 years+ - NCT06774872RecruitingPhase 2
Comparing two-drug HIV maintenance treatments
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
Paris, Île-de-France RegionAges 18 years+ - NCT06928090Enrolling by invitation
HIV trial testing two-med combo for first-time treatment
This trial studies a two-drug pill (DTG/3TC) for people who have never taken HIV medication before. It aims to see if this simpler treatment is effective and safe for controlling HIV-1.
DaejeonAges 19 years+ - NCT07202546RecruitingPhase 2
New oral HIV drug trial for people new to treatment
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
Bakersfield, CaliforniaAges 18 years+ - NCT06619288Recruiting
HIV treatment study comparing B/F/TAF to older drugs
This study tests a newer HIV medication, B/F/TAF, as a first-line treatment. It compares B/F/TAF with older combinations (TDF+3TC+EFV or DTG/3TC) to see how well it works for people who have never taken HIV meds.
Nantong, JiangsuAges 18 years+ - NCT07138144RecruitingPhase 4
Switching to a two-drug HIV pill vs. staying on three drugs
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
Mexico City, Mexico CityAges 18–70
What DTG/3TC is being studied for
Conditions with recruiting DTG/3TC studies.
Common questions
- Are there clinical trials studying DTG/3TC?
- Yes. Clin2 currently lists 6 recruiting studies that include DTG/3TC, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a DTG/3TC trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is DTG/3TC an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether DTG/3TC or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.